STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	1
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	2
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	2-3
Setting	5	Describe the setting, locations, and relevant dates, including periods	11-12
-		of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and	11
1		methods of selection of participants. Describe methods of follow-up	
		Case-control study—Give the eligibility criteria, and the sources	
		and methods of case ascertainment and control selection. Give the	
		rationale for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources	
		and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and	N/A
			IV/A
		number of exposed and unexposed	
		Case-control study—For matched studies, give matching criteria	
		and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	11,12,14,15
		confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	11
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10-12
Study size	10	Explain how the study size was arrived at	11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	11-12
Quantitutive variables	11	applicable, describe which groupings were chosen and why	11 12
Statistical methods	12	(a) Describe all statistical methods, including those used to control	11-13
Statistical methods	12	for confounding	11-13
		(b) Describe any methods used to examine subgroups and	11-12
		interactions	11-12
		(c) Explain how missing data were addressed	11-12
		(d) Cohort study—If applicable, explain how loss to follow-up was	11-12
		addressed	11
		Case-control study—If applicable, explain how matching of cases	
		and controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods	
		taking account of sampling strategy	

1	۵۱	Describe	anv	sensitivity	anals	1000
- (e)	Describe	anv	Sensitivity	anary	/Ses

Continued on next page

Results			T
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	11
		potentially eligible, examined for eligibility, confirmed eligible, included in the	
		study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	11,14,15
data		and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of	14,15
		interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over	14,15
		time	
		Case-control study—Report numbers in each exposure category, or summary	
		measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary	
		measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates	11,12,16-
		and their precision (eg, 95% confidence interval). Make clear which	21
		confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk	
		for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	N/A
		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	10
		imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	7-9
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information	on		
		Cive the service of funding and the note of the funders for the massest study and	1
Funding	22	Give the source of funding and the role of the funders for the present study and,	1

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.